Background: Sequential administration of platinum-based doublet therapy and then a taxane may reduce the risk of drug resistance and, therefore, improve treatment outcome. This study was designed to evaluate the efficacy and tolerability of sequential administration of irinotecan and cisplatin and then docetaxel in patients with advanced non-small cell lung cancer (NSCLC). Methods: Eligible patients received irinotecan in 60-mg/m 2 infusions for 30 to 60 minutes on days 1, 8, and 15, and cisplatin in 75-mg/m 2 infusions for 60 minutes on day 1 every 28 days for four cycles (IC). Regardless of the response, patients received up to four cycles of sequential docetaxel in 75-mg/m 2 infusions for 60 minutes. Results: Forty-six patients with histologically confirmed chemotherapy-naïve stage IIIB or IV NSCLC were enrolled, of whom 42 were evaluable. The response rate at completion of chemotherapy with IC was 45.2% (95% confidence interval [CI]: 30.2%-60.3%). Five patients had improvement of disease status during sequential docetaxel, and seven patients had disease progression. Progressionfree survival was 8.0 months (95% CI: 5.4 -9.9 months), and the overall median survival was 14.6 months (95% CI: 9.8 -17.9 months). The 1-, 2-, and 3-year survival rates were 54.3%, 22.6%, and 12.1%, respectively. The incidence of severe (ՆCTC V2 grade 3) neutropenia during IC was 23.9% compared with 95.7% for sequential docetaxel (p Ͻ 0.0001). Conclusion: Sequential administration of IC and then docetaxel is feasible and is associated with a prolonged progression-free survival, but the current data do not confirm an improvement in treatment outcome by the sequential approach.
P latinum-based combination chemotherapy prolongs survival of patients with advanced stage non-small cell lung cancer (NSCLC). 1 The combination of platinum with cytotoxic drugs such as gemcitabine, taxanes, or vinorelbine have become the standard first-line therapy for NSCLC. [2] [3] [4] Comparison studies have confirmed the efficacy of these doublet therapies to be similar, as are the novel modifications such as triplet therapy and non-platinum-based doublet therapy. [5] [6] [7] [8] [9] Sequential administration of a taxane after platinumbased doublet therapy is scientifically sound and potentially less toxic than platinum-based triplet therapy. Mathematical models suggest that sequential administration of drugs with different mechanisms of action could be superior to concurrent administration. 10, 11 An updated, computerized model of chemotherapy drug scheduling also suggested that sequential administration could optimize outcomes. 12 Clinically, it is known that docetaxel could be used for salvage for patients with platinum-resistant NSCLC. 13 The single-drug regimen attained a tumor response rate of 7.1% and improved median survival to 7.0 months. Thus, sequential administration of a taxane immediately after first-line chemotherapy may be associated with improved treatment outcome. The cytotoxic properties of the taxanes depends in part on an intact p53 pathway, so the sequential use of a taxane after platinum-based chemotherapy could minimize the risk for drug resistance. 14, 15 Irinotecan (CPT-11, Campto) is a water-soluble camptothecin derivative that inhibits topoisomerase I, the intranuclear enzyme that relieves torsion in DNA during replication. Phase II studies of a combination of irinotecan and cisplatin (IC) have demonstrated efficacy in advanced NSCLC. 16 -19 The tumor response rate ranged from 25.0% to 37.8%, and the median survival was 7.4 to 10.0 months. Diarrhea was common but was well tolerated with the aid of a simple antidiarrhea agent. A comparative study of IC versus cisplatin and vindesine showed that IC was associated with a higher tumor response rate and similar median survival. 20 The combination was not included in the major American study (ECOG 1594 ) that compared the efficacy of four platinumbased first-line regimens, but a Japanese comparative study has confirmed that this combination achieved results similar to those for cisplatin combined with paclitaxel, docetaxel, or gemcitabine. 21 IC is recognized as a standard regimen for advanced NSCLC.
Although maintenance therapy with single-agent thirdgeneration cytotoxic drugs after platinum-based doublet is not capable of improving overall survival, 22, 23 use of alternate agent as sequential therapy has not been thoroughly studied. We hypothesized that sequential administration of IC and then docetaxel may attain greater efficacy without added toxicity. We chose irinotecan and cisplatin for their different mechanisms of action and nonoverlapping toxicity. Docetaxel is a standard second-line therapy for patients who had failed a platinum-based regimen. 13 This phase II study was conducted to evaluate the efficacy and tolerability of sequential administration of IC and then docetaxel in patients with advanced NSCLC.
METHODS

Eligibility
Patients aged between 18 and 70 years, with Eastern Cooperative Oncology Group performance scale Յ2 and stage IIIb or IV histologically/cytologically proven NSCLC were eligible for this study. All patients were chemotherapy naïve and had measurable disease at one or more disease sites measured by computed tomography (CT). Prior irradiation for NSCLC was permitted, but the measurable or evaluable nonmeasurable disease had to be completely outside the radiation portal. All enrolled patients were capable of understanding the diagnosis and the nature of the trial, and signed the consent form. Patients with symptomatic central nervous system metastases, concurrent malignancy, uncontrolled hypercalcemia, inflammatory bowel disease, and life-threatening medical conditions were excluded. Patients with impaired renal and liver functions, and women who were pregnant or lactating were also excluded. The minimal liver function requirement was total bilirubin no more than twice the upper limit of normal (ULN); aspartate aminotransferase or alanine aminotransferase no more than three times ULN; and alkaline phosphatase no more than three times ULN without liver or bone metastasis, or no more than five times ULN. The serum creatinine requirement was Ͻ140 M, and creatinine clearance was Ն60 ml/min.
Study Design
This was a single-arm, open-label, single-center phase II study. The primary objective was to assess the tumor response rate after sequential administration of IC and then single-agent docetaxel for the treatment of advanced NSCLC. The secondary objectives were time to progression (TTP), median survival, safety, and change in quality of life (QOL) during treatment. The additional benefit of docetaxel for reducing tumor size in patients with stable disease or a partial response to IC and its role as salvage therapy for patients with resistant disease was also studied. The study was conducted according to the Principles of Good Clinical Practice. The protocol and consent form (in both Chinese and English) were approved by the joint research ethics committee of the Prince of Wales Hospital and The Chinese University of Hong Kong.
Treatment
Irinotecan (60 mg/m 2 ; 250-ml normal saline infusion) was administered for 30 to 60 minutes on days 1, 8, and 15, every 28 days. Cisplatin was given at the standard dosage of 75 mg/m 2 in a 250-ml normal saline infusion for 1 hour on day 15. Routine antiemetics of metoclopramide (10 mg) and dexamethasone (10 mg) were administered intravenously before irinotecan infusion. Ondansetron and dexamethasone were given on day 15 before cisplatin infusion. Docetaxel (75 mg/m 2 , in 250 ml of normal saline) was infused for 60 minutes on day 1 of a 3-week cycle. Patients received prophylactic dexamethasone and antiemetics.
Patients who attained a partial response or stable disease with IC completed four cycles before switching to docetaxel. If the disease progressed or toxicity became unacceptable to the patient or investigator, the patient switched to docetaxel before completion of four cycles of IC. All patients received a maximum of four cycles of docetaxel. If the sequential regimen under study failed, the investigator had the discretion of prescribing other salvage therapy.
The IC dose was modified according to hematologic or renal toxicity. Irinotecan infusion was delayed if the neutrophil count was less than 500/mm 2 on days 8 or 15. If neutropenia was persistent after 7 days, the dose was not given. If the neutrophil count was less than 1000/mm 3 and the platelet count was Ͻ75,000/mm 2 on day 1, the subsequent cycle was delayed for 7 to 14 days. If the neutrophil count was less than 1000/mm 3 and the platelet count was less 75,000/mm 2 on day 15, the cisplatin infusion was delayed for 7 days. If neutropenia was persistent after 7 days, the dose was not given. Serum creatinine was monitored before each cisplatin infusion, and the dose was reduced by 50% if creatinine clearance was between 40 and 60 ml/min. If creatinine clearance was less than 40 ml/min, the cisplatin infusion was discontinued.
Treatment was discontinued in the presence of disease progression, intolerable toxicity, concurrent serious medical conditions, or completion of eight cycles of therapy. Radical radiation was offered to patients with local regional stage IIIb disease after completion of chemotherapy and confirmation of tumor response status. Palliative radiation was given for symptomatic disease. The treatment field involved the site of measurable disease only after discontinuation of the study treatment.
Assessment
At enrollment, all patients underwent complete medical history and physical examination, laboratory assessment, chest radiograph, and CT scan of the thorax and upper abdomen. Laboratory assessment included complete blood count (CBC), renal function tests, liver function tests, serum calcium, coagulation profile, blood glucose, and 24-hour urine collection for creatinine clearance and total protein. Bone scan and CT scan of the brain were indicated for symptomatic patients.
Hematologic toxicity was monitored by CBC on days 1, 8, 15, and 22 of each cycle of IC and on days 1 and 8 of each cycle of docetaxel. Laboratory assessments, with the exception of blood glucose, serum calcium, and coagulation profile, were repeated on day 1 of each cycle of chemotherapy. Chest radiograph was repeated monthly. Imaging of the measurable tumor by CT scan was repeated every two cycles. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 2.0 (NCI CTC-V2), and tumor response was defined by the World Health Organization criteria. 24 All radiological imaging was reviewed by a designated radiologist and investigator but not by an independent panel. Time to progression was defined as the time from randomization to the date of documentation of disease progression. Overall survival was measured from the date of randomization to the date of death.
QOL Assessment
QOL was measured by the validated Chinese translation of the European Organization of Research and Treatment of Cancer core questions on the Quality of Life Questionnaire, version 2 (QLQ-C30). 25, 26 Patients completed this self-administered questionnaire on day 1 of each cycle and at monthly follow-up visits until the date of confirmed tumor progression.
Statistical Methods
The primary endpoint of the study was to investigate the tumor response rate of the sequential regimen of IC followed by docetaxel. Simon's optimal two-stage design was used for estimation of sample size. Assuming 30% responders for the null hypothesis versus 50% responders for the alternative hypothesis, 46 patients were needed for 80% power using a 5% level test. Fifteen evaluable patients were enrolled in the first stage, and if there were fewer than five partial responses, the study would be stopped. Otherwise, accrual would continue until the target sample size of 46 evaluable patients was reached.
Intent-to-treat analyses were performed for all enrolled patients. Overall survival and TTP were estimated using the Kaplan-Meier method. The log-rank test was used for comparison of time-to-event endpoints, and the chi-square method was used for testing differences in toxicity and response rates. Frequency of toxicity was tabulated according to the most severe toxicity during each cycle of chemotherapy. The change in mean scores of QOL domains and symptoms was compared with the baseline score using the Wilcoxon rank-sum test.
RESULTS
Patient Characteristics
Forty-six patients were enrolled between January 2002 and November 2003. Patients' characteristics are summarized in Table 1 . A high proportion of patients with stage IIIB disease were eligible for this study (43.4%). Only 15.2% of patients had the histologic subtype of squamous cell carcinoma. The remaining patients had adenocarcinoma or NSCLC without exact subtyping. All 46 patients received at least one cycle of chemotherapy, but four patients were discontinued from the study before tumor evaluation. One patient died from non-treatment-related complications, one patient required urgent radiotherapy for superior vena cava obstruction, one patient declined further therapy, and one patient refused platinum-based treatment and requested to switch to docetaxel after one cycle of IC. Forty-two patients were evaluable for tumor response, but all 46 patients were analyzed for survival according to the intention-to-treat analysis.
Treatment
One hundred sixty-one cycles of IC were given to 46 patients, with a median of four cycles per patient. Forty-two of the 46 patients were evaluable and eligible to continue with sequential administration of docetaxel, five of whom dropped out for reasons of patient refusal (three patients) and toxicity (two patients). The remaining 37 patients received 134 cycles of single-agent docetaxel, with a median of four cycles per patient. Radical radiotherapy was given to four patients with stage IIIb disease. Other patients with stage IIIb disease did not receive radical radiotherapy for the reason of pleural effusion, 6 contralateral supraclavicular lymph node metastasis, 7 poor lung function, 1 and refusal. 1 Palliative radiation was given to 18 patients for symptom control at various extrathoracic sites, including bone, axilla, brain, and supraclavicular lymph nodes. Twenty-three patients received salvage chemotherapy, including gemcitabine, pemetrexed, or vinorelbine, and eight patients received gefitinib as secondor third-line therapy. In addition, 14 patients used Chinese herbal medicine as the only salvage/supportive therapy.
Tumor Response and Survival
Treatment outcomes are summarized in Table 2 . None of the patients achieved a complete response. The tumor 
months).
Using the first day of docetaxel infusion as a reference point, the progression-free survival was 6.1 months (95% CI: 4.7-6.5 months). The overall median survival was 14.6 months (95% CI: 9.8 -17.9 months); Figure 1 . The 1-, 2-, and 3-year survival rates were 54.3%, 22.6%, and 12.1%, respectively.
Toxicity
Hematologic and nonhematologic toxicities are summarized in Tables 3 and 4 , respectively. IC was well tolerated. Only 23.9% of patients experienced severe (ՆCTC V2 grade 3) neutropenia during IC administration. Sequential administration of docetaxel was more myelotoxic than IC. The grade 3/4 neutropenia rate of 95.7% was significantly higher than that of IC (p Ͻ 0.001). Four patients required treatment deferral, and seven patients experienced neutropenic fever during docetaxel administration compared with none during IC administration. Nonhematologic toxicities were relatively mild and well tolerated with both regimens. Anorexia, nausea, and vomiting were more common with the cisplatin-containing regimen (p ϭ 0.02, 0.007, and 0.002, respectively). Fatigue was more common with the taxane regimen, but the difference was not statistically significant.
QOL
The changes in QOL from baseline during IC administration and from the last day of IC during docetaxel administration were documented. Tables 5 and 6 summarize the domains with significant changes (p Ͻ 0.05). Forty-three patients participated in the QOL assessment, and the compliance rate for completion was high for all cycles (100%, 81.45%, 81.4%, and 81.4% for cycles 1, 2, 3, and 4, respectively). The compliance rates for QOL assessment for docetaxel cycles 1 to 4 were 97.3%, 97.3%, 91.1%, and 75.7%, respectively. Patients noticed significant improvement from baseline in the physical, role, and cognitive domains during IC administration, and the benefits were sustained during docetaxel administration. The change in QOL score was persistently significant in IC cycles 1 to 4, and the change from the end of IC administration through four cycles of docetaxel was minimal. Nevertheless, there was a substantial increase in treatment-related symptoms of anorexia, nausea, and diarrhea. The problem of nausea and anorexia started from cycle 1 of IC administration, whereas diarrhea became significant only at cycle 3. All of these symptoms improved when patients were switched to docetaxel. There was a significant increase of symptoms suggestive of peripheral neuropathy towards the last two cycles of docetaxel.
DISCUSSION
Sequential administration of platinum-based doublet therapy and then a taxane is theoretically and biologically sound. The rationale for sequential chemotherapy includes the activity of a taxane in platinum-resistant NSCLC and maximization of drug delivery. 15, 27 In this phase II study, a high tumor response rate of 47.6% was observed with IC (95% CI: 32.5%-62.7%). Nevertheless, administration of sequential docetaxel did not increase the overall response rate. Four of 20 patients (20%) who attained a partial response with IC progressed with docetaxel, and only 3 of 22 patients (13.6%) who attained stable disease or progressive disease with IC had a tumor response with docetaxel. As result, the final tumor response rate was slightly lower than after four cycles of IC. Similar results were observed in the first study reported by the Southwest Oncology Group (SWOG), of sequential combination chemotherapy of gemcitabine and carboplatin and then palcitaxel. 28 The tumor response rate after three cycles of gemcitabine and carboplatin was 25%. Of the 25 patients who received sequential paclitaxel, four (13%) attained a higher response, 13 (52%) remained stable, and nine (36%) progressed. The second SWOG study, which randomized patients to either gemcitabine and carboplatin followed by paclitaxel or vinorelbine and cisplatin followed by docetaxel, reported the same findings. 29 Only 6% and 5%, respectively, of patients had improvements in tumor response with sequential taxane therapy. In this study, only patients with nonprogressive disease after three cycles of gemcitabine/ifosphamide/cisplatin (GIP) were randomized. Tumor response rates for patients who received three cycles of GIP and then three cycles of paclitaxel was numerically lower than those for six cycles of GIP (36% versus 44%; p ϭ 0.18). Furthermore, the high tumor response rate reported in our study could be related to ethnicity. The Japanese four-arm study comparing platinum-based doublet reported a persistent higher response rate than did the Western counterparts. 5, 21 Observation from multiple clinical trials with sequential taxane after platinum-based combination chemotherapy is contrary to the preclinical evidence of taxane activity in platinum-resistant lung cancer. This study resulted in progression free survival of 8.04 months (95% CI: 5.4 -9.9 months), which seems to be an improvement over IC alone from historic control. 30 Using the first day of docetaxel is used as a reference point, progression-free survival with sequential docetaxel was 6.1 months (95% CI: 4.7-6.5 months). This also seems to be an improvement to single-agent docetaxel as second-line therapy. 13 Administration of docetaxel sequentially after platinum-based doublet therapy may potentially improve the progression-free survival. Nevertheless, the study population included a high proportion of patients with stage IIIB disease who would have better treatment outcomes than would patients with stage IV disease. The treatment duration of this study was longer than for other studies; the patients received four cycles of IC and then four cycles of docetaxel. In the two SWOG studies of sequential chemotherapy, only three cycles of platinum-based doublet therapy and three subsequent cycles of a taxane were given; the median TTP ranged from 4.0 to 4.9 months. A recent randomized study comparing immediate versus delayed docetaxel after induction chemotherapy of gemcitabine and carboplatin reported significant prolongation of progression-free survival (6.5 versus 2.8 months; p Ͻ 0.0001), favoring the sequential administration. 31 The long progression-free period observed in our study is in line with their findings, although we cannot conclude with confidence from our single-arm study.
Two randomized studies on maintenance therapy after platinum-based doublet using the same agent did not show improvement in overall survival. 22, 23 Brodowicz et al. 23 randomized patients to receive either gemcitabine or observation immediately after tumor response or stable disease to firstline therapy of gemcitabine and cisplatin, and they reported overall survival of 13 months and 11 months, respectively (p ϭ 0.19). Use of alternate cytotoxic drug immediately after platinum-based doublet was shown to improve progressionfree survival, but the difference in overall survival was statistically insignificant. 31 We report an impressive median survival of 14.6 months, but we are reluctant to conclude that sequential therapy with either the same or an alternate agent could prolong overall survival.
The 4-week schedule of IC was well tolerated. Bone marrow suppression was mild, and only 6.5% of patients had diarrhea of grade 2 or higher. By comparison, the sequential administration of docetaxel was significantly more myelotoxic. The incidence of grade 3 to 4 neutropenia was higher than any other studies of single-agent docetaxel as secondline therapy. 13, 32 Seven patients (18.9%) experienced neutropenic fever during docetaxel administration, but none of these fevers were fatal. Edelman et al. 28 also reported a significantly higher incidence of grade 3 and 4 neutropenia (70%) with sequential combination chemotherapy of platinum-based doublet therapy followed by docetaxel than with the sequential combination involving paclitaxel (47%). The combination of irinotecan and docetaxel was not particularly myelotoxic. This is similar to a previous study reporting the incidence of grade 3 and 4 neutropenia to be 21.6%. 33 Even with the concurrent administration of a three-drug combination using irinotecan, paclitaxel, and carboplatin, the incidence of grade 3 and 4 neutropenia was only 40%. 34 Therefore, the most likely explanation for the significant neutropenia of docetaxel is the sequential administration immediately after platinum-based doublet therapy.
Edelman et al. 28 propose several reasons for sequential combination chemotherapy not meeting the statistical criteria for further study. These included the choice of agents that were not truly non-cross resistant, large tumor burden in stage IV disease, and modest efficacy of a taxane as a second-line therapy. Our results are consistent with their explanation. Edelman et al. 28 used gemcitabine or vinorelbine for their platinum-based doublet therapy, whereas we used irinotecan. To this effect, all three nontaxane third-generation cytotoxic drugs have failed to demonstrate non-cross resistance with a taxane. We had a high proportion of patients with stage IIIB disease, but we were not able to demonstrate a definite improvement in treatment outcomes. Furthermore, we have shown that the tumor response rate to sequential administration of a taxane was not higher than the use of the drug as a second-line therapy.
In conclusion, we have demonstrated sequential administration of irinotecan and cisplatin and then docetaxel to be feasible and associated with prolonged progression-free survival, but we have not been able to demonstrate convincingly that the sequential approach would improve the overall treatment outcomes.
